SDC1 and lymphoma: For instance, as tumours become more aggressive, heparanase activity is enhanced in myeloma, lymphomas or breast cancer, increasing both the number of exosomes released and the amount of syndecan-1, VEGF and HGF molecules exposed on their surface (65), making them more available for detection.